Congress returns to Washington next week with some important decisions to make in a short time. One of their immediate priorities should be stabilizing the Health Insurance Marketplaces to protect the millions of Americans who rely on them for health coverage. Policymakers should remove uncertainty about continued funding for cost-sharing reductions. This funding helps cover out-of-pocket costs for lower-income people who purchase coverage through the exchanges. Nearly 60% of marketplace customers rely on these funds – that’s 7 million people, all who earn less than 250% of the federal poverty level. If funding is not continued, consumers will have fewer coverage options. Insurers will exit the marketplaces. Premiums will rise. And hospital resources will be strained as they care for more uninsured Americans. We and other stakeholders agree funding the cost-sharing subsidies is essential to creating stable marketplaces and promoting greater access to coverage. But Congress and the administration have yet to say whether the funding will continue. We urge Congress to take quick action and appropriate the necessary funds.

Headline
Average annual premiums for employer-based family health coverage reached $28,303 in 2026, up 5% from 2025, according to the latest KFF annual survey on…
Headline
The Centers for Medicare & Medicaid Services Oct. 20 published two qualifying payment amount audits under the No Surprises Act. The audits were of…
Headline
A new AHA report warns that access to care is increasingly at risk in rural communities as workforce shortages, financial pressures and policy changes threaten…
Headline
The AHA has released a social media toolkit with sample posts and graphics encouraging people to sign up for 2027 health coverage via the Health Insurance…
Headline
Multiple changes to transparency in coverage requirements for insurers were finalized Oct. 5 by the Departments of the Treasury, Labor, and Health and Human…
Headline
The Centers for Medicare & Medicaid Services Sept. 30 finalized its Global Benchmark for Efficient Drug Pricing Model, also known as the GLOBE Model. The…